title: ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response.
abstract: The tyrosine kinase inhibitor STI571 (imatinib mesylate, Gleevec) is an effective treatment for chronic myeloid leukemia (CML). We examined bone marrow samples from 53 patients with CML who were receiving STI571 in 3 multicenter phase 2 trials to assess morphologic changes and cytogenetic response to this drug. In most patients with initially increased blasts, the bone marrow blast count rapidly decreased during STI571 therapy. Reductions in cellularity, the myeloid/erythroid ratio (commonly with relative erythroid hyperplasia), and reticulin fibrosis (if present pretreatment) also were seen in most patients, resulting in an appearance resembling normal marrow in many cases. Eighteen patients (34%) had some degree of cytogenetic response. Surprisingly, these striking morphologic changes occurred irrespective of any cytogenetic response to STI571. Thus, STI571 seems to affect the differentiation of CML cells in vivo, causing even extensively Philadelphia chromosome-positive hematopoiesis to exhibitfeatures resembling normal hematopoiesis.
authors.affiliation: Dept of Pathology, Baystate Medical Center, Springfield, MA 01199, USA.
authors.forename: Robert P
authors.initials: RP
authors.lastname: Hasserjian
authors.forename: Federica
authors.initials: F
authors.lastname: Boecklin
authors.forename: Sally
authors.initials: S
authors.lastname: Parker
authors.forename: Andy
authors.initials: A
authors.lastname: Chase
authors.forename: Sunanda
authors.initials: S
authors.lastname: Dhar
authors.forename: Michael
authors.initials: M
authors.lastname: Zaiac
authors.forename: Eduardo
authors.initials: E
authors.lastname: Olavarria
authors.forename: Irvin
authors.initials: I
authors.lastname: Lampert
authors.forename: Kristin
authors.initials: K
authors.lastname: Henry
authors.forename: Jane F
authors.initials: JF
authors.lastname: Apperley
authors.forename: John M
authors.initials: JM
authors.lastname: Goldman
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001706:Biopsy; D001853:Bone Marrow / Q000473:pathology*; D002452:Cell Count; D002454:Cell Differentiation; D020732:Cytogenetic Analysis; D005355:Fibrosis; D006410:Hematopoiesis; D006412:Hematopoietic Stem Cells / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D008533:Megakaryocytes / Q000473:pathology; D009336:Necrosis; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate